Dual PI3K/mTOR inhibitors have shown to reduce cell proliferation of PIK3CA mutant tumors in mice43 and phase I clinical studies.44 However, this effect was not seen in cell lines where KRAS and PIK3CA mutations co-occurred.45 When combining the dual PI3K/mTOR inhibitor with an MEK inhibitor, significant tumor reduction was seen in KRAS mutant tumors.46,47 No data are available on combined PI3K/mTOR and MEK inhibition for patients with KRAS A146 mCRC specifically. The gene discussed is KRAS; the disease is neoplasm.